Study of the Impact on Survival of a Paradigm Shift in the Therapeutic Strategy of Patients With Advanced Ovarian Cancer

Recruiting

• Conditions: Ovarian Cancer

• Registration Number: NCT06907771
• Lead Sponsor: University Hospital, Strasbourg, France

Brief Summary

Ovarian cancer is the 8th leading cause of cancer-related death in women. Its prognosis is poor, with diagnosis often made at an advanced stage.

Patient management has evolved in recent years with more radical surgeries and the introduction of maintenance treatment following neoadjuvant chemotherapy.

Detailed Description

Not available

Study Timeline

• Study Start: 2024-04-22
• Status Verified: 2025-03
• Study First Submitted: 2025-03-26
• Study First Submitted QC: 2025-03-26
• Last Update Submitted: 2025-03-26
• Study First Posted: 2025-04-02
• Last Update Posted: 2025-04-02
• Primary Completion: 2025-12-22
• Study Completion: 2025-12-22

Recruitment & Eligibility

• Status: RECRUITING
• Sex: Female
• Target Recruitment: 130

Inclusion Criteria

• Adult patient (≥18 years old)
• Operated on at the HUS between January 1, 2010 and December 31, 2022
• Having undergone primary or interval cytoreductive surgery
• Suffering from stage FIGO IIIC or IV high-grade serous carcinoma of ovarian origin

Exclusion Criteria

• Patiente ayant exprimé son opposition à la réutilisation de ses données à des fins de recherches scientifiques.
• Autres types histologiques de cancer de l'ovaire
• Stades de la maladie FIGO I, II, IIIA et IIIC
• Chirurgie de clôture.

Study & Design

• Study Type: OBSERVATIONAL
• Study Design: Not specified

Primary Outcome Measures

Name	Time	Method
Study of progression-free survival at 36 months	At 36 months

Trial Locations

Locations (1)

Service de Gynécologique et d'Obstétrique - CHU de Strasbourg - France; 🇫🇷 Strasbourg, France